Navigation Links
70% of Contact Lens Cases are Contaminated and Nearly 1 in 4 are Never Replaced - a Serious Problem Eye Doctors Want Fixed, WatchDog Group Reports
Date:4/10/2009

New Contact Lens and Case Timer Solves Widespread Problem

ST. LOUIS, April 10 /PRNewswire/ -- There are over 38 million contact lens wearers in the U.S. and children are the fastest growing segment. The contact lens industry is enjoying great success, but there is danger growing under those lenses.

Danger in the form of hard to pronounce words like fusarium keratitis and acanthamoeba keratitis. These are nasty words that are causing eye health complications from minor eye infections to blindness. Thousands of patients will visit their doctors today, unnecessarily.

And the culprit? Up to 80% of all complications are traced back to poor patient compliance. More often than not, contact lens problems are simply caused by their owners' lack of awareness of proper care techniques. Most contact lens wearers simply don't know the basic rules. Basic rules like throwing away lens cases frequently. A frightening reality when the end result can cause blindness.

Frightening statistics

Contact lens cases need to be replaced at least every 3 months and monthly replacement is strongly recommended. Lens cases are hotbeds for dangerous bacteria and fungi. Yet over 70% of cases are contaminated from overuse and 23% (nearly 1 in 4) of all contact lens wearers never replace their lens case. Never! Also, over 60% of contact lenses are worn past their expiration date - a recipe for disaster.

These are unacceptable statistics. Contact lenses and lens cases are medical devices not fashion accessories, yet most patients get the impression that contact lenses are non-prescriptive and lens care is irrelevant.

The chair of the American Optometric Association, Paul Klein, O.D., recently wrote to the 36,000 professional members of the AOA:

         Doctor, look in the mirror. When was the last time you told a
       
'/>"/>
SOURCE WatchDog Group LC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Amcat Partners With Gryphon to Provide Comprehensive and Guaranteed Do Not Call (DNC) Compliance Solution for Outbound Contact Activities
2. Service-to-Sales Transformation at Contact Centers Hinges on Soft Skills
3. Presentation at Bio Contact Quebec 2007
4. ILC Dover Launches Revolutionary ArmorFlex (R) Pharmaceutical Product Contact Film
5. ACUVUE(R) 2 COLOURS(R) Brand Contact Lenses Launches Virtual Eye Makeover Tool
6. Worlds First Non-Contact Thermometer for Children Now Available at Walgreens Nationwide
7. ECO2 Plastics to File for FDA Approval for Food-Contact Applications
8. Contact Lens Shift Can Compromise Vision of People with Astigmatism with the Blink of an Eye
9. Contact lenses purchased over Internet may place individuals at risk for harmful eyecare practices
10. Eye Care Lacking in Many Who Buy Contact Lenses Online
11. Contact lenses with circuits, lights a possible platform for superhuman vision
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 2Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 3Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 4Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 5Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 6Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 7Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 8Particle Sciences and IES Engineers Cooperate on High Potency Compound Handling Capabilities 2Particle Sciences and IES Engineers Cooperate on High Potency Compound Handling Capabilities 3Global Announces Contract To Acquire New Business 2Wound Management Technologies Inc Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies Inc 12648 1Wound Management Technologies Inc Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies Inc 12648 2Carbon Design Innovations Inc Introduces Carbon Nanotube Probe Technology for Atomic Force Microscopy CNT Probes Deliver New Level of AFM Imaging P 12645 1Carbon Design Innovations Inc Introduces Carbon Nanotube Probe Technology for Atomic Force Microscopy CNT Probes Deliver New Level of AFM Imaging P 12645 2Carbon Design Innovations Inc Introduces Carbon Nanotube Probe Technology for Atomic Force Microscopy CNT Probes Deliver New Level of AFM Imaging P 12645 3Finances Trigger American Reluctance to Spend More on Healthier Foods 49018 1Finances Trigger American Reluctance to Spend More on Healthier Foods 49018 2
Other Medicine Technology:Biomira Selects PX-866 as Clinical Development Candidate and,Presents Promising Preclinical Data at AACR 2Biomira Selects PX-866 as Clinical Development Candidate and,Presents Promising Preclinical Data at AACR 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 2Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 4Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 5Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 6Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 8Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 9